Greish, K.; Alawadhi, A.; Jaradat, A.; Almarabheh, A.; AlMadhi, M.; Jawad, J.; Alsaffar, B.; Alalawi, E.; Alsayyad, A.; Merza, A.; Alalawi, B.; Qayed, D.; Humaidan, A.; Al Qahtani, M. Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old. Vaccines2022, 10, 586.
Greish, K.; Alawadhi, A.; Jaradat, A.; Almarabheh, A.; AlMadhi, M.; Jawad, J.; Alsaffar, B.; Alalawi, E.; Alsayyad, A.; Merza, A.; Alalawi, B.; Qayed, D.; Humaidan, A.; Al Qahtani, M. Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old. Vaccines 2022, 10, 586.
Background and Objectives: In the current Covid-19 pandemic, children below the age of 12 could manifest Covid-19 symptoms and serve as a reservoir for the virus in the community. The present study was conducted to evaluate the reactogenicity, and immunogenicity of BBIBP-CorV, prior to involving this age group in the vaccination program in the kingdom of Bahrain. Subjects and Methods: The study included 582 children from 3 to 12 years old of Bahraini and non-Bahraini nationality, all of which contributed to the reactogenicity study. Of those, 401 contributed to the immunogenicity study. All children received 2 doses of BBIBP-CorV inactivated virus 3 weeks apart. To assess reactogenicity, children were followed up for 5 weeks to evaluate any vaccine-related adverse events (AE). To assess immunogenicity, blood was collected on day 0 and day 35 to assess antibody titer against S, N, and neutralizing antibody. Results: Of the 582 participants, (45.4%) were female, (54.61%) were male, with 49% in 9-12 age group. Of the 401 children contributing to the immunogenicity study, 274 (68.3%) had no prior exposure to Covid-19. The overall incidence of AE was 27.7%. No significant difference was found among different age groups. The most frequent AE was local (at the injection site) and occurred in 16% of children, followed by fever in 9.3%. No serious adverse events were reported. The Seroconversion rate was 100% among children with no prior exposure to Covid-19. Children with previous Covid-19 exposure had higher averages of anti-S (2379 U/ml compared to 409.1), anti-N (177.6 U/ml compared to 30.9) and neutralizing antibody (93.7 U/ml compared to 77.1) than children with no prior exposure at day 35. Conclusions: Two doses of COVID-19 BBIBP-CorV on the subjects aged between 3 to 12 has good safety and tolerance and can induce an effective immune response and neutralizing antibody titer.
COVID-19; BBIBP-CorV; children 3-12 years old; the anti-spike; Anti-nucleocapsid; Neutralizing antibody
MEDICINE & PHARMACOLOGY, General Medical Research
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.